QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial 期刊论文 CANCER COMMUNICATIONS, 2019, 卷号: 39 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：113/0  |  提交时间：2019/12/05 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I 期刊论文 2019, 卷号: 39, 期号: 1, 页码: 28 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：43/0  |  提交时间：2020/01/03 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients 期刊论文 Journal of Clinical Oncology, 2017, 卷号: 35 作者:  Shi Y., Li J., Xu J., Cheng Y., Liu W., Cheng Y., Bai L., Zhang Y., He X., Luo Y., Liu Y., Yao Q., Li Y., Qin S., Hu X., Guo Y., Sun Y. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05